Retrosynthetic analysis of the structure of imidazo[1,5-a]quinoxalines made it possible to develop new convenient procedures for preparation of these compounds by reaction of 3-(alpha-chlorobenzyl)-1,2-dihydroquinoxalin-2-one with potassium thiocyanate or isocyanate as synthetic equivalent of the two-membered N- = C+ building blocks and by reaction of 3-(alpha-aminobenzyl)-1,2-dihydroquinoxalin-2-one with carbon disulfide, triethoxymethane, aromatic aldehydes, or acetic anhydride as synthetic equivalent of the one-membered RC3+ synthon.
Retrosynthetic analysis of the structure of imidazo[1,5-a]quinoxalines made it possible to develop new convenient procedures for preparation of these compounds by reaction of 3-(alpha-chlorobenzyl)-1,2-dihydroquinoxalin-2-one with potassium thiocyanate or isocyanate as synthetic equivalent of the two-membered N- = C+ building blocks and by reaction of 3-(alpha-aminobenzyl)-1,2-dihydroquinoxalin-2-one with carbon disulfide, triethoxymethane, aromatic aldehydes, or acetic anhydride as synthetic equivalent of the one-membered RC3+ synthon.
PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS
申请人:GLYCOREGIMMUNE, INC.
公开号:US20160158258A1
公开(公告)日:2016-06-09
In accordance with some embodiments herein, methods and compositions for prevention and treatment of inflammatory conditions are provided. In some embodiments, compositions comprising NKT-2 activators, for example miltefosine are provided. In some embodiments, the compositions further comprise sulfatide and/or a RAR agonist. In some embodiments, the compositions comprise activators of Type II NKT cells, and/or inhibitors of Type I NKT cells.
[EN] PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS<br/>[FR] PRÉVENTION ET TRAITEMENT DE PATHOLOGIES INFLAMMATOIRES
申请人:GLYCOREGIMMUNE INC
公开号:WO2016094226A1
公开(公告)日:2016-06-16
In accordance with some embodiments herein, methods and compositions for prevention and treatment of inflammatory conditions are provided. In some embodiments, compositions comprising NKT-2 activators, for example miltefosine are provided. In some embodiments, the compositions further comprise sulfatide and/or a RAR agonist. In some embodiments, the compositions comprise activators of Type II NKT cells, and/or inhibitors of Type I NKT cells.